Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta - A study on maternal cholestasis model

Placenta

Volumn 36, Issue 5, 2015, Pages 545-551

  Wu, W B ^a   Xu, Y Y ^a   Cheng, W W ^a   Wang, Y X ^a   Liu, Y ^a   Huang, D ^a   Zhang, H J ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Farnesoid X receptor; Farnesoid X receptor agonist; Intrahepatic cholestasis of pregnancy; Oxidative stress; Placenta; WAY 362450

Indexed keywords

BILE ACID; BILE SALT EXPORT PUMP; ETHINYLESTRADIOL; FARNESOID X RECEPTOR; PEROXIREDOXIN 1; PEROXIREDOXIN 3; TUROFEXORATE ISOPROPYL; AZEPINE DERIVATIVE; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; INDOLE DERIVATIVE; PEROXIREDOXIN; PRDX1 PROTEIN, MOUSE; PRDX3 PROTEIN, MOUSE; WAY-362450;

AMNION FLUID; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; EDEMA; FEMALE; HUMAN; HUMAN CELL; LIVER LEVEL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLACENTA DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TROPHOBLAST; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; CHOLESTASIS, INTRAHEPATIC; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PLACENTA; PRECLINICAL STUDY; PREGNANCY; PREGNANCY COMPLICATIONS;

ANIMALS; APOPTOSIS; AZEPINES; BILE ACIDS AND SALTS; CASE-CONTROL STUDIES; CHOLESTASIS, INTRAHEPATIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EDEMA; FEMALE; HUMANS; INDOLES; MICE, INBRED C57BL; OXIDATIVE STRESS; PEROXIREDOXIN III; PEROXIREDOXINS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84926999803     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2015.02.005     Document Type: Article

References (45)

1. V. Geenes, and C. Williamson Intrahepatic cholestasis of pregnancy World J Gastroenterol 15 17 2009 2049 2066
2. V. Geenes, L.C. Chappell, P.T. Seed, P.J. Steer, M. Knight, and C. Williamson Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study Hepatology 59 4 2014 1482 1491
3. L. Brouwers, M.P. Koster, G.C. Page-Christiaens, H. Kemperman, J. Boon, and I.M. Evers Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels Am J Obstet Gynecol 212 1 2014 100.e1-100.e7
4. M. Arrese, R.I. Macias, O. Briz, M.J. Perez, and J.J. Marin Molecular pathogenesis of intrahepatic cholestasis of pregnancy Expert Rev Mol Med 10 2008 e9
5. C. Williamson, and V. Geenes Intrahepatic cholestasis of pregnancy Obstet Gynecol 124 1 2014 120 133
6. S.W. Van Mil, A. Milona, P.H. Dixon, R. Mullenbach, V.L. Geenes, and J. Chambers Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy Gastroenterology 133 2 2007 507 516
7. F. Lammert, H.U. Marschall, A. Glantz, and S. Matern Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management J Hepatol 33 6 2000 1012 1021
8. C. Williamson, L.M. Hems, D.G. Goulis, I. Walker, J. Chambers, and O. Donaldson Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group BJOG 111 7 2004 676 681
9. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, and A. Luk Identification of a nuclear receptor for bile acids Science 284 5418 1999 1362 1365
10. A. Milona, B.M. Owen, J.F. Cobbold, E.C. Willemsen, I.J. Cox, and M. Boudjelal Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function Hepatology 52 4 2010 1341 1349
11. D. Oztekin, I. Aydal, O. Oztekin, S. Okcu, R. Borekci, and S. Tinar Predicting fetal asphyxia in intrahepatic cholestasis of pregnancy Arch Gynecol Obstet 280 6 2009 975 979
12. Y. Bacq, L. Sentilhes, H.B. Reyes, A. Glantz, J. Kondrackiene, and T. Binder Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis Gastroenterology 143 6 2012 1492 1501
13. M. Rook, J. Vargas, A. Caughey, P. Bacchetti, P. Rosenthal, and L. Bull Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort PLoS One 7 3 2012 e28343
14. D. Joshi, A. James, A. Quaglia, R.H. Westbrook, and M.A. Heneghan Liver disease in pregnancy Lancet 375 9714 2010 594 605
15. M. Trauner, and J.L. Boyer Bile salt transporters: molecular characterization, function, and regulation Physiol Rev 83 2 2003 633 671
16. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, and F.J. Gonzalez Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 6 2000 731 744
17. T.T. Lu, M. Makishima, J.J. Repa, K. Schoonjans, T.A. Kerr, and J. Auwerx Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors Mol Cell 6 3 2000 507 515
18. B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, D.D. McKee, and L.B. Moore A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol Cell 6 3 2000 517 526
19. S. Fiorucci, C. Clerici, E. Antonelli, S. Orlandi, B. Goodwin, and B.M. Sadeghpour Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis J Pharmacol Exp Ther 313 2 2005 604 612
20. G. Papacleovoulou, S. Abu-Hayyeh, E. Nikolopoulou, O. Briz, B.M. Owen, and V. Nikolova Maternal cholestasis during pregnancy programs metabolic disease in offspring J Clin Invest 123 7 2013 3172 3181
21. W. Wu, B. Zhu, X. Peng, M. Zhou, D. Jia, and J. Gu Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease Biochem Biophys Res Commun 443 1 2014 68 73
22. R.I. Macias, M.J. Pascual, A. Bravo, M.P. Alcalde, M.G. Larena, and M.V. St-Pierre Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem Hepatology 31 4 2000 975 983
23. M.A. Serrano, R.I. Macias, O. Briz, M.J. Monte, A.G. Blazquez, and C. Williamson Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta Placenta 28 2-3 2007 107 117
24. V.L. Geenes, P.H. Dixon, J. Chambers, S. Raguz, J.J. Marin, and K.K. Bhakoo Characterisation of the nuclear receptors FXR, PXR and CAR in normal and cholestatic placenta Placenta 32 7 2011 535 537
25. S.G. Rhee, S.W. Kang, T.S. Chang, W. Jeong, and K. Kim Peroxiredoxin, a novel family of peroxidases IUBMB Life 52 1-2 2001 35 41
26. C.A. Neumann, J. Cao, and Y. Manevich Peroxiredoxin 1 and its role in cell signaling Cell Cycle 8 24 2009 4072 4078
27. L. Li, W. Shoji, H. Oshima, M. Obinata, M. Fukumoto, and N. Kanno Crucial role of peroxiredoxin III in placental antioxidant defense of mice FEBS Lett 582 16 2008 2431 2434
28. R.J. Sokol, M.S. Straka, R. Dahl, M.W. Devereaux, B. Yerushalmi, and E. Gumpricht Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids Pediatr Res 49 4 2001 519 531
29. M.J. Perez, R.I. Macias, and J.J. Marin Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid Placenta 27 1 2006 34 41
30. M.J. Perez, R.I. Macias, C. Duran, M.J. Monte, J.M. Gonzalez-Buitrago, and J.J. Marin Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid J Hepatol 43 2 2005 324 332
31. J.J. Marin, R.I. Macias, and M.A. Serrano The hepatobiliary-like excretory function of the placenta. A review Placenta 24 5 2003 431 438
32. R.I. Macias, J.J. Marin, and M.A. Serrano Excretion of biliary compounds during intrauterine life World J Gastroenterol 15 7 2009 817 828
33. V. Gurung, P. Middleton, S.J. Milan, W. Hague, and J.G. Thornton Interventions for treating cholestasis in pregnancy Cochrane Database Syst Rev 6 2013 CD000493
34. G. Paumgartner, and U. Beuers Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology 36 3 2002 525 531
35. T. Joutsiniemi, S. Timonen, R. Leino, P. Palo, and U. Ekblad Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial Arch Gynecol Obstet 289 3 2014 541 547
36. L.C. Chappell, V. Gurung, P.T. Seed, J. Chambers, C. Williamson, and J.G. Thornton Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial BMJ 344 2012 e3799
37. R.F. Burrows, O. Clavisi, and E. Burrows Interventions for treating cholestasis in pregnancy Cochrane Database Syst Rev 4 2001 CD000493
38. J. Palma, H. Reyes, J. Ribalta, I. Hernandez, L. Sandoval, and R. Almuna Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo J Hepatol 27 6 1997 1022 1028
39. P.L. Nicastri, A. Diaferia, M. Tartagni, P. Loizzi, and M. Fanelli A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy Br J Obstet Gynaecol 105 11 1998 1205 1207
40. Y. Liu, J. Binz, M.J. Numerick, S. Dennis, G. Luo, and B. Desai Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis J Clin Invest 112 11 2003 1678 1687
41. B.A. Neuschwander-Tetri Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease Curr Gastroenterol Rep 14 1 2012 55 62
42. D. Merk, D. Steinhilber, and M. Schubert-Zsilavecz Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators Future Med Chem 4 8 2012 1015 1036
43. R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action Clin Res Hepatol Gastroenterol 36 Suppl. 1 2012 S3 S12
44. B. Flatt, R. Martin, T.L. Wang, P. Mahaney, B. Murphy, and X.H. Gu Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) J Med Chem 52 4 2009 904 907
45. C.T. Dolphin, D.J. Beckett, A. Janmohamed, T.E. Cullingford, R.L. Smith, and E.A. Shephard The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein J Biol Chem 273 46 1998 30599 30607